Emerging antiretroviral drug interactions

Paul A. Pham, Charles Flexner

Research output: Contribution to journalArticlepeer-review


With HIV-infected patients living longer and recommendations to initiate antiretrovirals (ARVs) being made earlier, the likelihood for potential drug-drug interactions between ARVs and concurrent medications used to manage co-morbid conditions will increase. In order to maximize the clinical benefit and minimize potential toxicity of ARVs and co-administered medications, it is important for clinicians to recognize significant drug-drug interactions. This article highlights clinically significant drug-drug interactions with antituberculosis agents, antimalarials, anticoagulants, chemotherapeutic agents and pulmonary antihypertensive agents when they are co-administered with newer ARVs (e.g. darunavir, raltegravir, maraviroc and etravirine).

Original languageEnglish (US)
Article numberdkq448
Pages (from-to)235-239
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number2
StatePublished - Feb 2011


  • Anticoagulants
  • Antituberculosis
  • Chemotherapy
  • HIV
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Emerging antiretroviral drug interactions'. Together they form a unique fingerprint.

Cite this